Clinical Trial Update: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous T-cells engineered to target KRAS mutations in combination with a KRAS-directed vaccine for metastatic cancers; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastrointestinal Cancer
• Genitourinary Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• Autologous KRAS-targeted T-cell therapy
• KRAS-targeted vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Solid Cancers, Colorectal Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING